These therapies can be cost-prohibitive and may require multiple sessions, limiting accessibility for a broader patient population
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a leading treatment in the fields of diabetes and obesity, with recent preclinical and clinical studies indicating significant benefits in the management and treatment of MASLD
In a 2025 review, the authors describe this species as occupying an extraordinary niche in the human gut, and a model organism studied for its ability to modulate human health and gut microbiome structure.13 In animal studies, it has slowed the development and progression of diabetes , obesity , and irritable bowel disease .14 In human trials, it has helped participants reduce their BMI and improve their diabetic markers.12 Its effects on obesity and diabetes have been recreated in humans as well
Theyre not wrong, but heres the thing: The alternatives either disappeared or became unaffordable overnight
Fever accompanying constipation : Could indicate infection or inflammatory process
The most severe side effects were seen with diarrhea
